Myriad Genetics, Inc. (NASDAQ: MYGN) is making waves at the 2025 ASCO Annual Meeting, presenting seven new research studies ...

In addition to the MRD oral abstract, additional research highlights include: “We have an exciting, diverse, and sizable slate of oncology results being presented at ASCO this year, where each ...

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look ...

Fintel reports that on May 21, 2025, Scotiabank downgraded their outlook for Myriad Genetics (NasdaqGS:MYGN) from Sector ...

Former President Joe Biden was diagnosed with prostate cancer on Friday, according to media reports. While the diagnosis, ...

Highlights,Myriad Genetics shows varying shifts in institutional ownership, reflecting diverse strategic positions.,Recent financial data reveals modest earnings performance amidst revenue challenges.

Highlights,Institutional portfolio adjustments reflect varying confidence levels in Myriad Genetics' trajectory.,Stock ratings exhibit notable revisions with a cautious stance on valuation.,Financial ...

S. Louise Phanstiel holds the position of Chairman for Myriad Genetics, Inc. She is also on the board of 5 other companies. In the past Ms. Phanstiel occupied the position of President-Specialty ...

For the first time, doctors have treated a baby born with a rare, life-threatening genetic disorder with a gene-editing therapy scientists tailored to specifically repair his unique mutation.

Arun Durvasula has received funding from the National Institutes of Health and the National Institute of Science. Sitting in my doctor’s examination room, I was surprised when she told me ...

Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests ...